117 related articles for article (PubMed ID: 20693771)
1. [Clinical manifestations and treatment of chronic eosinophilic leukemia (CEL)/idiopathic hypereosinophilic syndrome (HES) in Japan].
Sada A; Matsui T
Rinsho Ketsueki; 2010 Jul; 51(7):515-25. PubMed ID: 20693771
[No Abstract] [Full Text] [Related]
2. Soft tissue and skeletal involvement in FIP1L1-PDGFR-alpha positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission.
Malagola M; Martinelli G; Rondoni M; Ottaviani E; Piccaluga PP; Ricci P; Visani G; Baccarani M
Haematologica; 2004 Aug; 89(8):ECR25. PubMed ID: 15339694
[No Abstract] [Full Text] [Related]
3. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.
Wang LN; Pan Q; Fu JF; Shi JY; Jin J; Li JM; Hu J; Zhao WL; Chen Z; Chen SJ
Chin Med J (Engl); 2008 May; 121(10):867-73. PubMed ID: 18706197
[TBL] [Abstract][Full Text] [Related]
4. Primary resistance to imatinib in Fip1-like 1-platelet-derived growth factor receptor alpha-positive eosinophilic leukemia.
Simon D; Salemi S; Yousefi S; Simon HU
J Allergy Clin Immunol; 2008 Apr; 121(4):1054-6. PubMed ID: 18234315
[No Abstract] [Full Text] [Related]
5. Rapid reversal of quadraparesis in chronic eosinophilic leukaemia expressing the FIP1L1-PDGFRA transcript after therapy with imatinib.
Hus M; Helbig G; Cioch M; Szczepanska-Szerej H; Wieczorek P; Woźniak M; Kozinska J; Morawska M; Dmoszynska A; Kyrcz-Krzemien S; Kata D
Leuk Res; 2011 Mar; 35(3):e15-7. PubMed ID: 21093052
[No Abstract] [Full Text] [Related]
6. Chronic eosinophilic leukaemia revealed by lymphomatoid papulosis: the role of the FIP1-like 1-platelet-derived growth factor receptor alpha fusion gene.
Thuny C; Gaudy-Marqueste C; Nicol I; Gabert J; Costello R; Grob JJ; Richard MA
J Eur Acad Dermatol Venereol; 2010 Feb; 24(2):234-5. PubMed ID: 19686260
[No Abstract] [Full Text] [Related]
7. Chronic eosinophilic leukemia presenting with mouth and penile ulcers.
Najera JE; Harn L
Am J Med; 2012 Aug; 125(8):e5-6. PubMed ID: 22681908
[No Abstract] [Full Text] [Related]
8. [Oncogene Fip1-likeL/PDGFRalpha as a target for imatinib in patients with hypereosinophilic syndrome and chronic eosinophilic leukemia. A novel look at pathogenesis and therapy].
Helbig G; Stella-Hołowiecka B; Hołowiecki J
Pol Arch Med Wewn; 2005 May; 113(5):490-7. PubMed ID: 16479834
[No Abstract] [Full Text] [Related]
9. [Studying of clinical and laboratory features of chronic eosinophilic leukemias /hypereosinophilic syndrome].
Zhang Y; Yu MH; Xu SC; Yang L; Yu Y; Hao YS; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):3-8. PubMed ID: 18512307
[TBL] [Abstract][Full Text] [Related]
10. [Hypereosinophilic syndrome--difficult-to-catch diagnosis. Targeted molecular diagnostics and treatment now possible thanks to gene discovery].
Jönsson S; Lewerin C; Jacobsson S; Wadenvik H
Lakartidningen; 2006 Sep 6-12; 103(36):2556-9. PubMed ID: 17007200
[No Abstract] [Full Text] [Related]
11. [Endomyocardial fibrosis in chronic eosinophilic leukemia].
Winter L; Zellweger MJ; Bremerich J
Rofo; 2009 Jul; 181(7):691-3. PubMed ID: 19401974
[No Abstract] [Full Text] [Related]
12. Extramedullary molecular evidence of the 5'KIAA1509/3'PDGFRB fusion gene in chronic eosinophilic leukemia.
Albano F; Anelli L; Zagaria A; Lonoce A; La Starza R; Liso V; Rocchi M; Specchia G
Leuk Res; 2008 Feb; 32(2):347-51. PubMed ID: 17681599
[TBL] [Abstract][Full Text] [Related]
13. Unexplained hypereosinophilia and the need for cytogenetic and molecular genetic analyses.
Smith KJ; Jacobson E; Hamza S; Skelton H
Arch Dermatol; 2004 May; 140(5):584-8. PubMed ID: 15148104
[TBL] [Abstract][Full Text] [Related]
14. Novel approaches to therapy of hypereosinophilic syndromes.
Simon HU; Cools J
Immunol Allergy Clin North Am; 2007 Aug; 27(3):519-27. PubMed ID: 17868862
[TBL] [Abstract][Full Text] [Related]
15. Management of F/P+/- hypereosinophilic syndromes: case report and treatment review.
Kalra A; Palaniswamy C; Kalra A; Wig N; Sood R
Am J Ther; 2012 Sep; 19(5):e146-51. PubMed ID: 20724910
[TBL] [Abstract][Full Text] [Related]
16. Molecular diagnosis and targeted therapy of a pediatric chronic eosinophilic leukemia patient carrying TPM3-PDGFRB fusion.
Li Z; Yang R; Zhao J; Yuan R; Lu Q; Li Q; Tse W
Pediatr Blood Cancer; 2011 Mar; 56(3):463-6. PubMed ID: 21072821
[TBL] [Abstract][Full Text] [Related]
17. [Chronic eosinophilic leukemia].
Ouakaa-Kchaou A; Belhadj N; Ennaifer R; Hefaiedh R; Elloumi H; Gargouri D; Ghorbel A
Tunis Med; 2009 Apr; 87(4):303. PubMed ID: 19835296
[No Abstract] [Full Text] [Related]
18. [A man with FIP1L1/PDGFRA-positive chronic eosinophilic leukemia].
Leeksma OC; de Ruiter GS; van der Hulst VP; Terpstra WE; Cools J; Vandenberghe P
Ned Tijdschr Geneeskd; 2006 Sep; 150(35):1936-43. PubMed ID: 16999279
[TBL] [Abstract][Full Text] [Related]
19. Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene.
Walz C; Curtis C; Schnittger S; Schultheis B; Metzgeroth G; Schoch C; Lengfelder E; Erben P; Müller MC; Haferlach T; Hochhaus A; Hehlmann R; Cross NC; Reiter A
Genes Chromosomes Cancer; 2006 Oct; 45(10):950-6. PubMed ID: 16845659
[TBL] [Abstract][Full Text] [Related]
20. Hypereosinophilic syndrome, chronic eosinophilic leukemia, and mast cell disease.
Pardanani A; Verstovsek S
Cancer J; 2007; 13(6):384-91. PubMed ID: 18032976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]